Idasanutlin is a potent (IC50 = 6 nM) and selective inhibitor of MDM2, the primary negative regulator of p53.1 It blocks the p53-MDM2 interaction activating the p53 pathway leading to cell cycle arrest and apoptosis. Idasanutlin has displayed efficacy in the treatment of multiple cancers alone and in combination with other chemotherapeutics.2-6
* VAT and and shipping costs not included. Errors and price changes excepted